All News

The attack on Medicare payments for advanced imaging services is intensifying in Washington as both lawmakers on Capitol Hill and regulators at the Centers for Medicare & Medicaid Services target them for cuts.

The media seems to be more interested in highlighting the cost of new prostate cancer medications than the important progress made in treating the second leading cause of cancer death in men.

Uroplasty, Inc. (Minneapolis) has announced that two additional private insurance payers will cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.

Short-term androgen deprivation therapy given in combination with radiation therapy to men with early-stage prostate cancer increased their chances of living longer compared with treatment with radiation therapy alone, according to a recent multicenter study.

The FDA has issued an updated safety communication warning health care providers and patients that transvaginal placement of mesh to repair pelvic organ prolapse may expose patients to greater risk than other surgical options.

The U.S. will face serious shortages in the combined work force of physicians, advanced practice nurses, and physician assistants over the next 2 decades, say researchers from the University of Pennsylvania, Philadelphia. By 2025, the physician shortage alone could reach 20%.

Nearly all patients with high-grade, noninvasive bladder cancer are not receiving the guideline-recommended care that would best protect them from recurrence?a finding characterized as alarming by researchers from the UCLA Jonsson Comprehensive Cancer Center.

A new minimally invasive surgical technique known as hidden incision endoscopic surgery (HIdES) makes scarring after pediatric kidney surgery virtually invisible, yet it is as effective as more common surgical methods, according to the urologist who developed it.

Using a human vaccine, researchers from Mayo Clinic, Rochester, MN and the United Kingdom appeared to cure well-established prostate tumors in mice, with no apparent side effects.

Urology drugs and devices that are in the pipeline from Bayer Healthcare, Tengion, Inc., Advantagene, Inc., Hybrigenics, and Vivus.

This article discusses the rising incidence of both fluoroquinolone resistance and serious post-biopsy infectious complications, and offers recommended preventive measures, including a new algorithm incorporating targeted antimicrobial prophylaxis based on rectal swab cultures.

Five-year follow-up of older patients with renal tumors less than 3 cm shows that minimally invasive surgery with tumor enucleation yields less tumor progression than either percutaneous radiofrequency ablation or active surveillance.